Vivet Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Vivet Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on the antibodies that block AAV gene therapy from reaching patients. One study measures how common neutralising antibodies against AAV3B are in healthy donors and adults with Wilson's disease, and another models how many patients an antibody-clearing enzyme could make treatable.
| Organization | ESGCT 2026 Attendance |
|---|---|
Vivet Therapeutics Paris, France | |
Develops liver-directed AAV gene therapies for rare diseases such as Wilson's disease, PFIC and cerebrotendinous xanthomatosis. | Poster Wed Oct 28 1:30pm–3:30pm Naturally immunised AAV patients: modeling responder rates and treatable populations using VTX‑PID (imlifidase) dose‑range data to achieve non‑inhibitory AAV neutralizing antibody titers Poster Thu Oct 29 2:00pm–4:00pm Prevalence of adeno-associated virus type 3B neutralizing antibodies in cohorts of healthy donors and Wilson’s disease adults |
Instantly find 20 buyers from Vivet Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction